

**SAUDI PHARMACEUTICAL INDUSTRIES
AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)
(A Saudi Joint Stock Company)
Condensed Consolidated Interim Financial Statements (Unaudited)
For the three-month and nine-month periods ended 30 September 2025
together with
Independent Auditor's Review Report**

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)
(A Saudi Joint Stock Company)
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
For the three-month and nine-month periods ended 30 September 2025

<u>Index</u>	<u>Page(s)</u>
Independent auditor’s review report on review of condensed consolidated financial statements	1-2
<u>Condensed consolidated interim financial statements:</u>	
Condensed consolidated statement of financial position	3
Condensed consolidated statement of profit or loss	4
Condensed consolidated statement of comprehensive income	5
Condensed consolidated statement of changes in equity	6
Condensed consolidated statement of cash flows	7– 8
Notes to the condensed consolidated interim financial statements	9 – 24



KPMG Professional Services Company

Roshn Front, Airport Road
P.O. Box 92876
Riyadh 11663
Kingdom of Saudi Arabia
Commercial Registration No 1010425494

Headquarters in Riyadh

شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية

واجهة روشن، طريق المطار
صندوق بريد ٩٢٨٧٦
الرياض ١١٦٦٣
المملكة العربية السعودية
سجل تجاري رقم ١٠١٠٤٢٥٤٩٤

المركز الرئيسي في الرياض

Independent auditor's report on review of condensed consolidated interim financial statements

To the Shareholders of Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO – ADDWAEIH COMPANY)

Introduction

We have reviewed the accompanying 30 September 2025 condensed consolidated interim financial statements of Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO – ADDWAEIH COMPANY) ("the Company") and its subsidiaries ("the Group") which comprises:

- the condensed consolidated statement of financial position as at 30 September 2025;
- the condensed consolidated statement of profit or loss for the three-month and nine-month periods ended 30 September 2025;
- the condensed consolidated statement of comprehensive income for the three-month and nine-month periods ended 30 September 2025;
- the condensed consolidated statement of changes in equity for the nine-month period ended 30 September 2025;
- the condensed consolidated statement of cash flows for the nine-month period ended 30 September 2025; and
- the notes to the condensed consolidated interim financial statements.

Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of review

We conducted our review in accordance with the International Standard on Review Engagements 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' that is endorsed in the Kingdom of Saudi Arabia. A review of condensed consolidated interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Independent auditor's report on review of condensed consolidated interim financial statements

To the Shareholders of Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO – ADDWAEIH COMPANY) (continued)

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying 30 September 2025 condensed consolidated interim financial statements of Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO – ADDWAEIH COMPANY) and its subsidiaries are not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia.

Emphasis of Matter – Comparative Information

We draw attention to note 23 to the condensed consolidated interim financial statements of the Company and its subsidiaries which indicates that the comparative information presented as at and for the three-month and nine-month periods ended 30 September 2024, have been restated. Our conclusion is not modified in respect of this matter.

KPMG Professional Services Company

Naif Abdulrahman Edrees
License No: 457



Riyadh on: 9 November 2025
Corresponding to 18 Jamada Al-Awal 1447H

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 September 2025

(All amounts in thousands of ~~SR~~, unless otherwise stated)

	Note	30 September 2025	31 December 2024 (Audited)
ASSETS			
Property, plant and equipment	5	1,553,434	1,573,629
Assets under construction	5	197,839	172,318
Intangible assets	6	96,442	102,296
Right-of-use assets	7	7,129	25,708
Equity-accounted investees	8	79,781	67,734
Deferred tax assets		26,489	21,397
Total non-current assets		1,961,114	1,963,082
Trade receivables	9	1,217,802	1,174,997
Inventories	10	635,884	646,091
Due from related parties	19	30,088	15,330
Investments at fair value through profit or loss (FVTPL)		492	480
Prepayments and other assets		241,499	242,225
Short term investments	11	166,440	155,000
Cash and cash equivalents	12	184,318	122,143
Total current assets		2,476,523	2,356,266
Total assets		4,437,637	4,319,348
EQUITY AND LIABILITIES			
Equity			
Share capital	1	1,200,000	1,200,000
Statutory reserve	1	360,685	360,685
Treasury shares	13	(19,937)	(19,937)
Foreign currency translation reserve		(24,917)	(43,348)
Share-based payments reserve		5,154	1,175
Retained earnings / (accumulated losses)		25,316	(120,273)
Equity attributable to Owners of the Company		1,546,301	1,378,302
Non-controlling interests		162,123	153,017
Total equity		1,708,424	1,531,319
Liabilities			
Loans and borrowings	14	697,823	462,463
Lease liabilities	7	5,258	8,367
Employees' end of service benefit obligations		199,554	222,300
Government grant		39,511	40,220
Contract liabilities	15	52,254	44,594
Total non-current liabilities		994,400	777,944
Loans and borrowings – current portion	14	725,687	1,038,670
Lease liabilities – current portion	7	1,750	3,043
Zakat and income tax payable	16	62,568	62,435
Trade and other payables		573,559	567,999
Dividends payable		167,799	168,108
Refund liabilities	15	203,450	169,830
Total current liabilities		1,734,813	2,010,085
Total liabilities		2,729,213	2,788,029
Total equity and liabilities		4,437,637	4,319,348

Abdulaziz Aloud

Chief Financial Officer

Ahmed Aljedai

Managing Director



Authorized Board Member

The accompanying notes from pages 9 to 24 form an integral part of these condensed consolidated interim financial statements

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS (UNAUDITED)

For the three-month and nine-month periods ended 30 September 2025

(All amounts in thousands of SAR , unless otherwise stated)

	Note	For the three-month period ended 30 September		For the nine-month period ended 30 September	
		2025	2024	2025	2024
Revenue	21	415,304	447,312	1,300,906	1,296,765
Cost of revenue		(212,393)	(231,640)	(675,024)	(653,823)
Gross profit		202,911	215,672	625,882	642,942
Selling and marketing expenses		(70,282)	(74,663)	(212,284)	(226,172)
General and administrative expenses		(62,350)	(94,419)	(185,240)	(220,766)
Research and development expenses		(13,760)	(13,163)	(41,694)	(43,906)
Other income / (expenses), net	17	13,138	5,362	38,636	(3,452)
Impairment loss on financial assets		(5,003)	(17,466)	(14,716)	(40,092)
Operating profit		64,654	21,323	210,584	108,554
Finance costs		(23,231)	(22,820)	(72,473)	(61,303)
Finance income		2,601	2,572	8,322	7,816
Share of results of equity-accounted investees	8	6,097	6,718	22,247	16,242
Profit before zakat and income tax		50,121	7,793	168,680	71,309
Zakat and income tax	16	(6,536)	(17,058)	(13,985)	(22,991)
Profit / (loss) for the period		43,585	(9,265)	154,695	48,318
Profit / (loss) attributable to:					
Owners of the Company		42,138	(11,048)	145,589	41,397
Non-controlling interests		1,447	1,783	9,106	6,921
		43,585	(9,265)	154,695	48,318
Earning / (loss) per share					
Basic and diluted (SAR)	18	0.35	(0.09)	1.22	0.35

Abdulaziz Aloud

Chief Financial Officer

Ahmed Aljedai

Managing Director



Authorized Board Member

The accompanying notes from pages 9 to 24 form an integral part of these condensed consolidated interim financial statements

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)
(A Saudi Joint Stock Company)
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
For the three-month and nine-month periods ended 30 September 2025
(All amounts in thousands of ~~SR~~, unless otherwise stated)

	<u>For the three-month period ended 30 September</u>		<u>For the nine-month period ended 30 September</u>	
	2025	2024 (Restated - note 23)	2025	2024 (Restated - note 23)
Profit / (loss) for the period	43,585	(9,265)	154,695	48,318
<u>Other comprehensive income</u>				
<i>Items that are or may be reclassified subsequently to profit or loss:</i>				
Foreign currency translation differences	<u>(908)</u>	4,233	<u>18,431</u>	4,884
Other comprehensive (loss) / income for the period	<u>(908)</u>	4,233	<u>18,431</u>	4,884
Total comprehensive income /(loss) for the period	<u>42,677</u>	<u>(5,032)</u>	<u>173,126</u>	<u>53,202</u>
Total comprehensive income / (loss) attributable to:				
Owners of the Company	41,230	(6,815)	164,020	46,281
Non-controlling interests	<u>1,447</u>	1,783	<u>9,106</u>	6,921
	<u>42,677</u>	<u>(5,032)</u>	<u>173,126</u>	<u>53,202</u>

Abdulaziz Aloud

Chief Financial Officer

Ahmed Aljedai

Managing Director



Authorized Board Member

The accompanying notes from pages 9 to 24 form an integral part of these condensed consolidated interim financial statements

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION (SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the nine-month period ended 30 September 2025

(All amounts in thousands of SAR , unless otherwise stated)

	Share capital	Statutory reserve	Treasury Shares	Foreign currency translation reserve	Share-based payment reserve	Retained earnings / (accumulated losses)	Equity attributable to Owners of the Company	Non-controlling interests	Total equity
Balance as at 1 January 2025	1,200,000	360,685	(19,937)	(43,348)	1,175	(120,273)	1,378,302	153,017	1,531,319
Profit for the period	-	-	-	-	-	145,589	145,589	9,106	154,695
Other comprehensive income for the period	-	-	-	18,431	-	-	18,431	-	18,431
Total comprehensive income	-	-	-	18,431	-	145,589	164,020	9,106	173,126
Share-based payment expense	-	-	-	-	3,979	-	3,979	-	3,979
Balance as at 30 September 2025	1,200,000	360,685	(19,937)	(24,917)	5,154	25,316	1,546,301	162,123	1,708,424
Balance as at 1 January 2024 (restated)	1,200,000	360,685	(8,002)	(42,032)	-	(135,472)	1,375,179	140,416	1,515,595
Profit for the period (restated – note 23)	-	-	-	-	-	41,397	41,397	6,921	48,318
Other comprehensive income for the period	-	-	-	4,884	-	-	4,884	-	4,884
Total comprehensive income (restated – note 23)	-	-	-	4,884	-	41,397	46,281	6,921	53,202
Purchase of treasury shares	-	-	(11,935)	-	-	-	(11,935)	-	(11,935)
Balance as at 30 September 2024 (restated)	1,200,000	360,685	(19,937)	(37,148)	-	(94,075)	1,409,525	147,337	1,556,862

Abdulaziz Aloud

Chief Financial Officer

Ahmed Alyedai

Managing Director



Authorized Board Member

The accompanying notes from pages 9 to 24 form an integral part of these condensed consolidated interim financial statements.

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

For the nine-month period ended 30 September 2025

(All amounts in thousands of ﷲ, unless otherwise stated)

	30 September 2025	30 September 2024
		(Restated – note 23)
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit for the period	154,695	48,318
Adjustments for:		
Depreciation of property, plant and equipment	70,807	51,958
Depreciation of right-of-use assets	1,933	5,518
Assets under construction written off	2,005	1,283
Intangible assets written off	-	8
Amortization of intangible assets	9,646	8,269
Share of results of equity accounted investees	(22,247)	(16,242)
Gain on disposal of property, plant and equipment	(29,420)	(898)
Gain on termination of right-of-use assets and lease liabilities	(114)	-
Provision for sales/services discounts and returns	33,620	43,878
Shared based payment expense	3,979	-
Provision for net realizable value loss relating to inventories	26,506	3,344
Impairment loss on financial assets	14,716	40,092
Provision for employees' end of services benefits	20,339	23,460
Amortization of government grant	(1,426)	(272)
Terminated employees' legal claims charge / (reversal)	1,929	(6,983)
Finance costs	72,473	68,478
Finance income	(8,322)	(7,676)
Zakat and income tax	13,985	22,991
	365,104	285,526
Changes in:		
Inventories	(16,447)	(17,764)
Trade receivables and due from related parties	(62,933)	(421,079)
Prepayments and other assets (including advances for capital expenditures)	3,696	(56,415)
Contract liabilities	7,660	461
Trade and other payables	3,632	45,024
Cash generated from / (used in) operating activities	300,712	(164,247)
Finance costs paid	(53,706)	(59,329)
Finance income received	5,353	7,660
Finance cost paid relating to lease liabilities	(241)	(680)
Zakat and income tax paid	(18,981)	(19,338)
Employees' end of service benefit obligations paid	(43,085)	(85,625)
Net cash generated from / (used in) operating activities	190,052	(321,559)

Abdulaziz Aloud

Chief Financial Officer

Ahmed Aljedai

Managing Director



Authorized Board Member

The accompanying notes from pages 9 to 24 form an integral part of these condensed consolidated interim financial statements

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~SR~~, unless otherwise stated)

	30 September 2025	30 September 2024
		(Restated – note 23)
CASH FLOWS FROM INVESTING ACTIVITIES		
Additions to property, plant and equipment	(32,516)	(11,275)
Additions to intangible assets	(3,790)	(4,893)
Additions to short term investment	(136,440)	(203,000)
Disposal of short term investment	125,000	218,500
Proceeds from sale of property, plant and equipment	38,728	4,232
Dividends from joint venture	-	1,710
Additions to asset under construction	(18,131)	(49,035)
Net cash used in investing activities	(27,149)	(43,761)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from loans and borrowings	934,672	727,321
Repayment of loans and borrowings	(1,030,819)	(267,202)
Lease liabilities paid	(2,878)	(5,988)
Dividends paid	(308)	(1,154)
Purchase of treasury shares	-	(11,935)
Net cash (used in) / generated from financing activities	(99,333)	441,042
Net changes in cash and cash equivalents during the period	63,570	75,722
Foreign currency translation adjustments	(1,395)	1,979
Cash and cash equivalents at the beginning of the period	122,143	163,090
Cash and cash equivalents at the end of the period	184,318	240,791
	30 September 2025	30 September 2024
Non-cash transactions:		
Transfer to property, plant and equipment from asset under construction and right-of-use assets	22,758	1,701
Transfer to intangible assets from asset under construction	-	69,373
Dividend from equity-accounted investees	10,200	11,475

Abdulaziz Aloud

Chief Financial Officer

Aliamed Aljedai

Managing Director



Authorized Board Member

The accompanying notes from pages 9 to 24 form an integral part of these condensed consolidated interim financial statements.

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

1. THE COMPANY, ITS SUBSIDIARIES AND BUSINESS DESCRIPTION

Saudi Pharmaceutical Industries and Medical Appliances Corporation (the “Company” or the “Parent Company”) is a Saudi Joint Stock Company registered in Riyadh, Kingdom of Saudi Arabia under Commercial Registration number 1131006650 dated Rajab 6, 1406H (corresponding to March 16, 1986) with unified number 7000652177 and formed according to the Ministerial Resolution No. 884 dated Jumada Al-Awwal 10, 1406H (corresponding to January 21, 1986). These condensed consolidated interim financial statements (“interim financial statements”) as at and for the three-month and nine-month periods ended 30 September 2025 comprise the Company and its subsidiaries (together referred to as ‘the Group’).

The Company’s head office is in Buraidah city, King Abdul Aziz Road, Industrial City of Al-Qassim.

The Group is primarily involved in the manufacturing of pharmaceutical products, medicines for human use and wholesale and retail of medicines and related products, development and marketing of medical and pharmaceutical products, research and development in medical science activities, operating and maintaining the healthcare facilities and any investments in related industries, inside and outside the Kingdom of Saudi Arabia.

The Company’s share capital as at 30 September 2025 amounted to ~~ﷲ~~1,200 million (31 December 2024: ~~ﷲ~~1,200 million), consisting of 120 million fully paid and issued shares (31 December 2024: 120 million) of ~~ﷲ~~10 each.

Reference to the new Companies Law issued through Royal Decree M/132 on 1/12/1443H (corresponding to 30 June 2022) (hereinafter referred as "the Law") came into force on 26/6/1444 H (corresponding to 19 January 2023), the management has decided to amend Company’s by-laws by discontinuing the transfer of net income to statutory reserve as the Law makes the transfer as voluntary.

1.1 Subsidiaries

Name of subsidiary	Principal activities	Country of incorporation	Effective ownership	
			30 September 2025	31 December 2024
ARAC Healthcare Company	Pharmaceutical products distributor	Saudi Arabia	100%	100%
Pharmaceutical Industries Company for Distribution (a)	Pharmaceutical products distributor	Saudi Arabia	100%	100%
ARACOM Medical Company	Pharmaceutical products distributor	Saudi Arabia	100%	100%
ANORA Trading Company (b)	Pharmacy – retail	Saudi Arabia	99%	99%
Dammam Pharmaceutical Company	Pharmaceutical manufacturer	Saudi Arabia	100%	100%
Qassim Medical Service Company	Healthcare services provider	Saudi Arabia	57.27%	57.27%
SPIMACO Saudi Foundation – Algeria	Pharmaceutical products distributor	Algeria	100%	100%
SPIMACO Misr Company for Marketing (a)	Pharmaceutical products marketing	Egypt	100%	100%
SPIMACO Misr Company for Distribution (a)	Pharmaceutical products distributor	Egypt	100%	100%
SPIMACO Egypt Company	Pharmaceutical products distributor	Egypt	100%	100%
SPIMACO Misr for Pharmaceutical Industries	Pharmaceutical manufacturer	Egypt	90.59%	90.59%
SPIMACO Morocco for Pharmaceutical Industries	Pharmaceutical manufacturer	Morocco	78.68%	78.68%

a) There has been no commercial activity in these subsidiaries.

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ﷲ, unless otherwise stated)

1. THE COMPANY, ITS SUBSIDIARIES AND BUSINESS DESCRIPTION (Continued)

1.1 Subsidiaries (Continued)

b) ANORA Trading Company is a limited liability company, with a paid-up capital of ﷲ 0.3 million, and it is 99% owned by ARAC Healthcare Company (a wholly owned subsidiary of SPIMACO Group). On 17 November 2021, the partners of ANORA Trading Company, resolved to voluntarily liquidate the Company and appointed a legal liquidator for that purpose. The financial impact from the liquidation of ANORA Trading Company is immaterial as it has insignificant commercial activity and does not have financial commitments. The liquidation process has been completed and the final financial statements for liquidation purposes are expected to be completed and issued in the year 2025 after which, the liquidation process shall be concluded with the Ministry of Commerce (MOC) and Zakat, Tax and Customs Authority (ZATCA).

1.2 Associates and joint venture

Name	Principal activities	Country of incorporation	Effective shareholding	
			30 September 2025	31 December 2024
Arabian Medical Products Manufacturing Company (ENAYAH) – Joint venture	Manufacturing healthcare products	Saudi Arabia	51%	51%
CAD Middle East Pharmaceutical Company (CAD) – Associate	Active Pharmaceutical Ingredients manufacturing	Saudi Arabia	46.08%	46.08%
Tassili Arab Pharmaceutical Company (TAPHCO) – Associate	Pharmaceutical manufacturer	Algeria	22%	22%

2. BASIS OF PREPARATION

a) Statement of Compliance

These condensed consolidated interim financial statements have been prepared in accordance with the requirements of International Accounting Standard (IAS 34) ‘Interim Financial Reporting’ that is endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements issued by the Saudi Organization for Chartered and Professional Accountants (‘SOCPA’) and should be read in conjunction with the Group’s last annual consolidated financial statements as at and for the year ended 31 December 2024 (‘last annual financial statements’).

These condensed consolidated interim financial statements do not include all the information and disclosures required for a complete set of financial statements prepared in accordance with International Financial Reporting Standards (IFRS), however, selected accounting policies and explanatory disclosures have been included in order to explain the significant events and transactions that are required to obtain an understanding of the changes in the Group’s financial position and performance since the preparation of the last annual financial statements. These interim results may not be an indicator of the annual results of the Group.

b) Basis of measurement

These condensed consolidated interim financial statements have been prepared using the accrual basis of accounting and the going concern basis, on the historical cost basis, except for employees’ benefits plan which is measured at the present value of future obligations using the Projected Unit Credit method; financial instruments at fair value through profit and loss, which are measured at fair value; and investments in associates and joint ventures are measured using equity method accounting.

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ﷻ, unless otherwise stated)

2. BASIS OF PREPARATION (Continued)

c) Functional and presentation currency

These condensed consolidated interim financial statements are presented in Saudi Riyal (“ﷻ”) which is the Group’s functional and presentation currency. All amounts have been rounded off to the nearest thousands of Saudi Riyals unless otherwise stated.

d) Use of judgments and estimates

The Group makes certain estimates and assumptions regarding the future. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions.

The significant estimates made by the Group for managing the Group's accounting policies and the primary sources of estimating the unreliability remain the same as in the last annual financial statements.

3. MATERIAL ACCOUNTING POLICIES

The material accounting policies and calculation methods applied in preparing the condensed consolidated interim financial statements are consistent with those followed in preparing the Group’s last annual consolidated financial statements as at and for the year ended 31 December 2024 (“last annual financial statements”), except for the application of the new standards that became effective on 1 January 2025. The Group did not early adopt any other standard, interpretation or amendment issued but not yet effective.

4. NEW STANDARDS, AMENDMENTS TO STANDARDS AND INTERPRETATION

There are new standards and number of amendments to standards which are effective from 1 January 2025 and have been explained in Group’s annual consolidated financial Statements, but they do not have a material effect on the Group’s condensed consolidated interim financial statements.

5. PROPERTY, PLANT AND EQUIPMENT AND ASSETS UNDER CONSTRUCTION

	Property, Plant and Equipment (PPE)		Assets under Construction (AUC)	
	30 September 2025	31 December 2024	30 September 2025	31 December 2024
Cost:				
Opening balance	2,641,154	2,325,103	172,318	514,396
Additions	32,516	14,994	18,131	56,277
Disposals	(16,702)	(40,563)	-	-
Written off	-	-	(2,005)	(17,364)
Transfer in / (out)	22,758	315,225	(6,938)	(369,563)
Reclassification	-	8,169	-	(8,371)
Foreign currency translation	7,189	(5,500)	16,333	(4,365)
Reclassification from assets classified as held for sale	-	23,726	-	1,308
Closing balance	2,686,915	2,641,154	197,839	172,318

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of SAR , unless otherwise stated)

5. PROPERTY, PLANT AND EQUIPMENT AND ASSETS UNDER CONSTRUCTION (Continued)

	Property, Plant and Equipment (PPE)		Assets under Construction (AUC)	
	30 September 2025	31 December 2024	30 September 2025	31 December 2024
Accumulated depreciation:				
Opening balance	1,067,525	1,016,100	-	-
Charge for the period / year	70,807	69,328	-	-
Disposals during the period / year	(7,394)	(23,955)	-	-
Reclassification	-	(1,464)	-	-
Foreign currency translation	2,543	(1,928)	-	-
Reclassification from assets classified as held for sale	-	9,444	-	-
Closing balance	1,133,481	1,067,525	-	-
Net book value	1,553,434	1,573,629	197,839	172,318

During the nine-month period ended 30 September 2024, the Group acquired property, plant and equipment amounting to SAR 11.3 million. Assets with a carrying value of SAR 0.3 million were disposed off during the period, resulting in a Loss on disposal of SAR 0.9 million, which has been recognised within other income/(expenses) in the condensed consolidated interim financial statements. Depreciation expense for the nine-month period ended 30 September 2024 amounted to SAR 51.9 million.

6. INTANGIBLE ASSETS

	30 September 2025	31 December 2024
Cost:		
Opening balance	293,370	124,963
Additions	3,790	31,007
Written-off	-	(8)
Transfer from assets under construction (note 5)	-	54,338
Reclassification	-	202
Foreign currency translation	17	(6)
Reclassification from assets classified as held for sale	-	82,874
Closing balance	297,177	293,370
	30 September 2025	31 December 2024
Accumulated amortization:		
Opening balance	191,074	95,240
Charge for the period/year	9,646	11,498
Reclassification	-	1,465
Foreign currency translation	15	(3)
Reclassification from assets classified as held for sale	-	82,874
Closing balance	200,735	191,074
Net book value	96,442	102,296

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~SR~~, unless otherwise stated)

7. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

7.1 Right-of-use (ROU) assets

	30 September 2025	31 December 2024
Opening balance	25,708	32,204
Additions	-	346
Adjustments	-	703
Depreciation charge for the period/year	(1,933)	(3,881)
Disposals	(1,416)	(3,252)
Transfer to property, plant and equipment	(15,820)	-
Foreign currency translation	590	(412)
Closing balance	7,129	25,708

7.2 Lease liabilities

	30 September 2025	31 December 2024
Opening balance	11,410	18,504
Additions	-	346
Disposals	(1,530)	(3,621)
Adjustments	-	743
Finance cost	241	1,056
Effect of foreign currency translation	6	16
Payments for the period/year	(3,119)	(5,634)
Closing balance	7,008	11,410
Current portion	1,750	3,043
Non-current portion	5,258	8,367

8. EQUITY-ACCOUNTED INVESTEEES

	30 September 2025	31 December 2024
Opening balance	67,734	58,186
Share of result for the period / year	22,247	22,733
Dividends	(10,200)	(13,185)
Closing balance	79,781	67,734
	30 September 2025	31 December 2024
Arabian Medical Products Manufacturing Company (ENAYAH) – Joint Venture	79,781	67,734
Tassili Arab Pharmaceutical Company (TAPHCO) - Associate Company	-	-
CAD Middle East Pharmaceutical Company- Associate Company	-	-
	79,781	67,734

9. TRADE RECEIVABLES

	30 September 2025	31 December 2024
Trade receivables – third parties	1,322,285	1,264,546
Trade receivables – related parties (note 19)	37,879	37,879
	1,360,164	1,302,425
Less: impairment provision – third parties	(105,715)	(93,918)
Less: impairment provision – related parties (note 19)	(36,647)	(33,510)
	1,217,802	1,174,997

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

9. TRADE RECEIVABLES (Continued)

The movement in impairment provision is as follows:

	30 September 2025	31 December 2024
As at 1 January	93,918	112,854
Charge for the period / year	11,579	28,664
Written off	(636)	(47,494)
Reclassified from assets classified as held for sale	-	15
Effect of foreign currency translation	854	(121)
Closing balance	105,715	93,918

10. INVENTORIES

	30 September 2025	31 December 2024
Finished goods	405,175	443,006
Raw material	247,121	221,142
Stores and spares	30,217	28,659
Work-in-progress	21,851	7,819
Goods-in-transit	2,602	4,492
	706,966	705,118
Less: Provision for net realizable value (NRV) loss	(71,082)	(59,027)
	635,884	646,091

The movement of provision for net realizable value loss is as follows:

	30 September 2025	31 December 2024
Opening balance	59,027	64,237
Charge for the period / year*	26,506	1,171
Written-off	(14,600)	(234)
Effect of foreign currency translation	149	(6,352)
Reclassified from assets classified as held for sale	-	205
	71,082	59,027

*During the period ended 30 September 2025, the provision for net realizable value majorly includes expired and nearly expired goods.

11. SHORT TERM INVESTMENT

As of 30 September 2025, short term investment amounted to ~~ﷲ~~166.5 million (31 December 2024: ~~ﷲ~~155 million) represents Shariah-compliant deposits placed at one of the local banks, with profit margins ranging from 5.6% to 6% (31 December 2024: 5.36% to 5.7%), with a maturity of more than 3 months and less than a year.

12. CASH AND CASH EQUIVALENTS

	30 September 2025	31 December 2024
Cash at bank	153,744	120,974
Short term deposits*	29,800	-
Cash on hand	774	1,169
	184,318	122,143

*As at 30 September 2025, this represent short term deposit with an original maturity of less than 3 months.

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

13. TREASURY SHARES

During 2023, the Extraordinary General Assembly in its meeting held on Rabi Al'Akhir 30, 1445H (corresponding to 15 November 2023) approved the purchase of the Company's shares, with a maximum of 815,000 shares. The Company completed the purchase of 645,000 shares amounting to ~~ﷲ~~19.94 million to be allocated to the Employees' Long-term Incentives Program (LTIP) and be granted to high-performing employees. The program intends to attract, motivate, and retain employees responsible for the achievement of the Group's goals and strategies. The program provides a share-based payment plan for all eligible employees participating in the program by granting them shares in the Company upon completing the duration of service. The Group accounts for the share-based payment plan program as an equity-settled share-based payment.

There is no impact of treasury shares on these condensed consolidated interim financial statements for the nine-month period ended 30 September 2025.

14. LOANS AND BORROWINGS

	30 September 2025	31 December 2024
<u>Current</u>		
Islamic financing	330,360	1,024,353
Government loans	13,543	14,317
Short-term loans	381,784	-
	725,687	1,038,670
<u>Non-Current</u>		
Islamic financing	654,382	446,416
Government loans	43,441	16,047
	697,823	462,463

During the period ended 30 September 2025, the Group obtained additional loans amounting to ~~ﷲ~~ 934.7 million (31 December 2024: ~~ﷲ~~1,290 million) and repaid loans amounting to ~~ﷲ~~ 1,030.8 million (31 December 2024: ~~ﷲ~~ 890 million).

15. REFUND LIABILITIES AND CONTRACT LIABILITIES

15.1 Refund Liabilities

	30 September 2025	31 December 2024
Sales/services discounts provision:		
Opening balance	144,558	140,138
Discounts provision against sales / services	156,138	342,813
Actual discounts adjustment during the period/year	(120,204)	(338,393)
Closing balance	180,492	144,558
Sales returns:		
Opening balance	25,272	22,209
Charge for the period / year	9,930	23,713
Adjusted during the period / year	(12,244)	(21,863)
Liabilities classified as held for sale	-	1,213
Closing balance	22,958	25,272
Total refund liabilities – current	203,450	169,830

15.2 Contract Liabilities

	30 September 2025	31 December 2024
Contract liabilities - non current	52,254	44,594

This relates to advances received from AstraZeneca UK Limited per the investment agreement dated June 2018, to reserve manufacturing capacity at the oncology facility in Qassim. During the period, the Group has recognized ~~ﷲ~~ 4.8 million (31 December 2024: Nil) as revenue.

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

16. ZAKAT AND TAX PAYABLE

16.1 The movement in the zakat and income tax payable:

	30 September 2025	31 December 2024
Opening balance	62,435	48,450
Charge for the period / year	19,077	33,489
Paid during the period / year	(18,981)	(19,566)
Effect of foreign currency translation	37	62
	62,568	62,435

16.2 Status of zakat and income tax assessments

The Company submitted the zakat returns to the Zakat, Tax and Customs Authority (ZATCA) and obtained the zakat certificate till 2024.

During 2023, ZATCA issued the assessment for 2020, which resulted in additional liability of ~~ﷲ~~ 27.8 million. In 2024, following the submission of additional information as requested by ZATCA accompanied by a payment of ~~ﷲ~~ 5.3 million, ZATCA has reduced the liability to ~~ﷲ~~ 21.5 million. The management undertakes to accrue the provision amounting to ~~ﷲ~~ 16.2 million and continue the objection in front of the General Secretariat of Zakat, Tax and Customs Committees (GSTC). GSTC has upheld the decision of ZATCA. The Company has filed a review petition to GSTC.

During 2024, ZATCA issued the preliminary assessment for 2021 and 2022 which resulted in additional liability of ~~ﷲ~~ 17.6 million and ~~ﷲ~~ 0.86 million for 2021 and 2022, respectively. During the period, following the ZATCA approval, the Company has opted to file the Zakat declaration based on the new Zakat Implementing Regulations through the Ministerial Resolution (MR) No.1007 dated 29 February 2024. ZATCA has reviewed the revised calculation and issued the final assessment resulting in reduction of liability to ~~ﷲ~~ 4.1 million for 2021 and 2022 respectively.

During the period, the Company has submitted the return for 2023 based on new Zakat Implementing Regulations, ZATCA has reviewed the revised calculation and issued the final assessment which resulted in liability of ~~ﷲ~~ 8.5 million for 2023.

Further, the Company did not receive Zakat assessment for the year 2024 from ZATCA.

All subsidiaries are filing zakat and/or income tax returns regularly as per their country of incorporation regulations and no disputes have been raised which requires additional provisions.

17. OTHER INCOME / (EXPENSES), NET

	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	2024	2025	2024
		Restated – note 23		Restated – note 23
Gain / (loss) on disposal of property, plant and equipment	10,915	(898)	29,420	(898)
Terminated employees' legal claims (charge) / reversal (refer to note 22)	(1,990)	4,332	(1,929)	6,983
Amortization of government grant	475	15	1,426	272
Foreign exchange income / (loss)	(1,734)	3,095	1,126	(11,187)
Others	5,472	(1,182)	8,593	1,378
	13,138	5,362	38,636	(3,452)

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

18. EARNING PER SHARE

	30 September 2025	30 September 2024
Profit for the period attributable to the owners of the Company	145,589	41,397
Weighted average number of ordinary shares	119,355,000	119,755,564
Earning per share attributable to the owners of the Company (ﷲ)	1.22	0.35

The weighted average number of shares takes into account the weighted average effect of changes in treasury shares during the period.

	30 September 2025	30 September 2024
Issued ordinary shares at 1 January	120,000,000	120,000,000
Effect of treasury shares held	(645,000)	(244,436)
	119,355,000	119,755,564

There is immaterial dilutive effect on the basic earning per share of the Company.

Basic earnings per share has been calculated by dividing the profit attributable to the Shareholders of the Company over the weighted average number of ordinary shares during the period.

19. TRANSACTIONS AND BALANCES WITH RELATED PARTIES

Related parties represent major shareholders, directors and key management personnel of the Group, and companies of which they are principal owners, and any other entities controlled, jointly controlled or significantly influenced by them. The Group transacts with related parties in the ordinary course of its activities, as many of the Group's transactions and arrangements are based on signed agreements between the Group and those companies. None of the balances are secured.

19.1 Significant transactions

Name of related parties	Relationship	Nature of transactions	30 September 2025	30 September 2024
Arabian Medical Products Manufacturing Co. (ENAYAH)	Joint Venture	Dividends received	10,200	13,185
CAD Middle East Pharmaceutical Co.	Associate	Purchase of raw material	6,000	15,253
Arab Company for Drugs Industries and Medical Appliances (ACDIMA)	Shareholder	Research cost	-	979
Tassili Arab Pharmaceutical Co. (TAPHCO)	Associate	Sales	-	2,393

19.2 Due from related parties

Name of related parties	Nature of balance	30 September 2025	31 December 2024
Non-current			
CAD Middle East Pharmaceutical Co.	Non-commercial	42,444	42,444
Tassili Arab Pharmaceutical Co. (TAPHCO)	Non-commercial	32,583	32,583
Current			
Arabian Medical Products Manufacturing Co. (ENAYAH)	Non-commercial	19,087	8,887
CAD Middle East Pharmaceutical Co.	Non-commercial	14,072	9,514
Tassili Arab Pharmaceutical Co. (TAPHCO)	Commercial	37,879	37,879
		146,065	131,307
Less: impairment allowance		(114,745)	(111,608)
		31,320	19,699

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

19. TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Continued)

The movement of impairment provision during the period / year is as follows:

	30 September 2025	31 December 2024
Opening balance	111,608	103,213
Charge for the period/year	3,137	8,395
Closing balance	114,745	111,608

As at 30 September 2025, ~~ﷲ~~ 39.7 million (31 December 2024: ~~ﷲ~~ 38.96 million) included in trade and other payables is balance due to TAPHCO (a related party).

The non-commercial balance outstanding is as follows:

	30 September 2025	31 December 2024
Gross receivable	108,186	93,428
Less: impairment provision	(78,098)	(78,098)
	30,088	15,330

The commercial balance outstanding is as follows:

	30 September 2025	31 December 2024
Gross receivable	37,879	37,879
Less: impairment provision	(36,647)	(33,510)
	1,232	4,369

19.3 Remuneration of key management personnel

	30 September 2025	30 September 2024
Short term benefits	9,329	14,123
Share based payment expense	3,979	-
	13,308	14,123

20. FINANCIAL INSTRUMENTS

The classification methodology used in line with the annual consolidated financial statements for the year ended 31 December 2024. No transfers were recorded between Level 1, Level 2 or Level 3 for the three-month and nine-month periods ended 30 September 2025.

21. SEGMENT INFORMATION

The Group's principal business activities involve the manufacturing of pharmaceutical products under SPIMACO and its subsidiaries' brand names. The trading and distribution segment involves sales, marketing, and distribution of pharmaceutical, veterinary, medical equipment, and cosmetics products. Healthcare services represent maintaining and operating a secondary care hospital.

The Group is organized into business units based on its products and services and has three reportable segments. Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ('CODM'). The CODM has been determined to be the Chief Executive Officer as he is primarily responsible for the allocation of resources to segments and the assessment of the performance of each of the segments. The CEO uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group. The identified key segments are pharmaceutical manufacturing, trading and distribution services and healthcare services.

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of SAR , unless otherwise stated)

21. SEGMENT INFORMATION (Continued)

The Board of Directors reviews the operating results of the business separately to make decisions about resource allocation and performance assessment. Transactions between the operating segments are on terms approved by the management.

The following table represents the segregation of revenue by type:

Type of revenue	For the three-months period ended 30 September		For the nine-months period ended 30 September	
	2025	2024	2025	2024
Revenue from sale of products	368,853	407,426	1,154,703	1,170,100
Revenue from services	46,451	39,886	146,203	126,665
	415,304	447,312	1,300,906	1,296,765

The following table shows the disaggregation of revenues by the primary geographical markets and based on the Group's three strategic divisions, which are its reportable segments.

For the nine-month period ended 30 September 2025

Primary geographical markets	Pharmaceutical	Trading & Distribution	Healthcare	Total
	Manufacturing	Services	Services	
Kingdom of Saudi Arabia	1,012,227	65,876	134,412	1,212,515
Middle East	56,569	-	-	56,569
Egypt	8,136	-	-	8,136
Morocco	21,437	-	-	21,437
Algeria	-	2,249	-	2,249
	1,098,369	68,125	134,412	1,300,906
At a point in time	1,098,369	68,125	16,861	1,183,355
Over time	-	-	117,551	117,551
	1,098,369	68,125	134,412	1,300,906

For the nine-month period ended 30 September 2024

Primary geographical Markets	Pharmaceutical	Trading & Distribution	Healthcare	Total
	Manufacturing	Services	Services	
Kingdom of Saudi Arabia	894,054	122,751	124,023	1,140,828
Middle East	120,967	-	-	120,967
Egypt	3,069	2,335	-	5,404
Morocco	20,496	-	-	20,496
Algeria	2,380	6,690	-	9,070
	1,040,966	131,776	124,023	1,296,765
Timing of revenue recognition				
At a point in time	1,040,966	131,776	43,582	1,216,324
Over time	-	-	80,441	80,441
	1,040,966	131,776	124,023	1,296,765

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

21. SEGMENT INFORMATION (Continued)

Selected financial information categorized by these business segments as follows:

30 September 2025	Pharmaceutical Manufacturing	Trading & Distribution Services	Healthcare Services	Total
Revenues	1,098,369	68,125	134,412	1,300,906
Depreciation and amortization	(73,792)	(2,084)	(6,510)	(82,386)
Finance (cost) / income	(60,440)	(10,930)	7,219	(64,151)
Impairment loss on financial assets	(9,590)	(5,986)	860	(14,716)
Zakat / income tax expense	(6,762)	(2,226)	(4,997)	(13,985)
Share of results of equity- accounted investees	22,247	-	-	22,247
Profit/(loss) for the period	165,914	(35,672)	24,453	154,695
Profit/(loss) attributable to Owners of the Company	167,182	(35,672)	14,079	145,589
Total Assets	3,550,792	484,106	402,739	4,437,637
Total Liabilities	2,186,582	459,074	83,557	2,729,213

30 September 2024 (Restated-note 23)	Pharmaceutical Manufacturing	Trading & Distribution Services	Healthcare Services	Total
Revenue	1,040,966	131,776	124,023	1,296,765
Depreciation and amortization	(53,875)	(5,294)	(6,576)	(65,745)
Finance (cost) / income	(51,540)	(7,309)	5,362	(53,487)
Zakat / income tax expense	(18,408)	-	(4,583)	(22,991)
Impairment loss on financial assets	(11,462)	(28,630)	-	(40,092)
Share of results of equity accounted investees	16,242	-	-	16,242
Profit / (loss) for the period	114,633	(84,760)	18,445	48,318
Profit / (loss) attributable to Owners of the Company	115,602	(84,760)	10,555	41,397
Total Assets	3,586,938	452,140	362,430	4,401,508
Total Liabilities	2,345,037	429,599	69,982	2,844,618

22. CONTINGENT LIABILITIES AND CAPITAL COMMITMENTS

Contingent liabilities

As at 30 September 2025, the Group has letters of guarantee amounting to ~~ﷲ~~ 62.4 million (31 December 2024: ~~ﷲ~~ 71.9 million).

In addition, the Group has contingent liability against letter of credit amounting to ~~ﷲ~~ 4.4 million issued in the normal course of business (31 December 2024: ~~ﷲ~~ 4.5 million).

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

22. CONTINGENT LIABILITIES AND CAPITAL COMMITMENTS (Continued)

Legal contingencies

Terminated Employees' Legal Cases

There have been labour law claims filed by terminated employees against the Company. The Group is working with external legal counsels to assess the validity and potential liabilities associated with these claims. Due to the inherent uncertainty of litigation, the financial impact on the Group cannot be reliably estimated at this stage. It is important to note that the ultimate resolution of these legal cases, including potential settlements, judgments, or dismissals, may have a material impact on the Group's financial position, results of operations, and cash flows in future reporting periods. The Group will provide updates as significant developments occur or when more information becomes available. While the Group is still vigorously defending these claims amounting to ~~ﷲ~~ 10.3 million, it has a related provision of ~~ﷲ~~ 4.2 million as of 30 September 2025 (31 December 2024: ~~ﷲ~~ 4.9 million).

Other Legal Contingencies

During normal business operations, some cases arise against the Group and are currently being defended, but the ultimate outcome of these cases cannot be determined with certainty. Management believes that the results of these cases will not have a material impact on the Group's consolidated financial statements for the period ended 30 September 2025.

Capital commitments

As at 30 September 2025, the Group has capital commitments for purchase of property, plant and equipment and intangible assets amounting to ~~ﷲ~~ 60.2 million (31 December 2024: ~~ﷲ~~ 65.7 million).

23. PRIOR PERIODS' ADJUSTMENTS AND RECLASSIFICATIONS

During the prior year ended 31 December 2024, the Group discovered certain adjustments and reclassifications that have been corrected by restating each of the affected financial statement line items for prior periods in the consolidated financial statements for the year ended 31 December 2024.

The nature of such adjustments and its corresponding impact on the comparative period presented in the condensed consolidated interim statement of profit or loss for the three-month and nine-month periods ended 30 September 2025 is detailed below:

- A. The trade receivables included commercial receivables from a related party of the Group, Tassili Arab Pharmaceutical Company (TAPHCO). The management identified that the Expected Credit Loss (ECL) recognised on these receivables was understated and not performed in accordance with the requirements of IFRS 9 - Financial Instruments. This has resulted in charge of impairment loss on financial assets by ~~ﷲ~~ 3.99 million during the nine-month period ended 30 September 2024.
- B. The Group identified that certain assets included under "assets under construction" were available for use in 2023 and prior year(s), however, the management did not account for these assets as per IAS 16 "Property, Plant and Equipment" and IAS 38 "Intangible Assets", and did not recognize the depreciation / amortization expenses. The management has calculated the depreciation and amortization on respective assets as per the requirements of applicable accounting standards. This has resulted in restatement of the depreciation and amortization expense of ~~ﷲ~~ 3.8 million during the nine-month period ended 30 September 2024.
- C. The Group identified that the oncology/high-potent facility's construction was completed in 2022, meeting the condition to cease borrowing cost capitalization. However, borrowing costs continued to be capitalized beyond this point, which is not in line with the requirement of IAS 23 "Borrowing Costs". This resulted in adjustments to finance costs of ~~ﷲ~~ 10.86 million for the nine-month period ended 30 September 2024.

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

23. PRIOR PERIODS' ADJUSTMENTS AND RECLASSIFICATIONS (Continued)

- D. Qassim Medical Services Company ("a subsidiary") had performed the reassessment of the useful life of its hospital building in 2021 wherein the useful life of the building was reassessed from 20 years to 40 years. The Group had received government grant related to this building. During the year ended December 31, 2024, the Group identified that when the reassessment of the useful life of the hospital building was performed, the balance related to government grant was not adjusted. As per the requirement of IAS 20 "Accounting for Government Grants and Disclosure of Government Assistance", the amortization period for government grant should have changed from 20 years to 40 years. This has resulted in the adjustments to other income by ~~ﷲ~~ 0.78 million for the nine-month period ended 30 September 2024.
- E. The management identified that the Group had entered into a forward agreement in December 2023 to acquire the 15% shares of Dammam Pharmaceuticals (subsidiary) from subsidiary's non-controlling shareholder, Cooper Pharma. The group did not account for this agreement as per the requirement of IFRS 10 "Consolidated Financial Statements". The correction of this error has resulted in adjustment in the loss attributable to non-controlling interest by ~~ﷲ~~ 0.02 million and in the operating and financing cashflows by ~~ﷲ~~ 27 million for the nine-months period ended 30 September 2024.

a) Group reconciliation of Condensed Consolidated Statement of Cash flows for the nine-month period ended 30 September 2024 (Unaudited):

The following tables summarize the impacts on the condensed consolidated statement of cash flows for the nine-month period ended 30 September 2024:

	30 September 2024 - as previously reported	Restatements/ Reclassifications	30 September 2024 (restated)
Cash used in operating activities	(292,197)	(29,362)	(321,559)
Cash used in investing activities	(45,471)	1,710	(43,761)
Cash generated from financing activities	413,390	27,652	441,042

SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ~~ﷲ~~, unless otherwise stated)

23. PRIOR PERIODS' ADJUSTMENTS AND RECLASSIFICATIONS (Continued)

b) Group reconciliation of Condensed Consolidated Statement of Profit or Loss for the nine-month period ended 30 September 2024 (Unaudited):

The following tables summarize the impacts on the condensed consolidated statement of profit or loss for the nine-month period ended 30 September 2024:

	Note	30 September 2024 - as previously reported	Restate- ments	Reclassi- fications	30 September 2024 (restated)
Continuing Operations					
Revenue		1,295,799	-	966	1,296,765
Cost of revenue	B	(649,538)	(2,824)	(1,461)	(653,823)
Gross profit		646,261	(2,824)	(495)	642,942
Selling and marketing expenses		(225,412)		(760)	(226,172)
General and administrative expenses	B	(212,791)	(631)	(7,344)	(220,766)
Research and development expenses	B	(43,520)	(386)	-	(43,906)
Other income / (expenses), net	D	(2,676)	(777)	1	(3,452)
Impairment loss on financial asset	A	(36,099)	(3,993)	-	(40,092)
Operating profit		125,763	(8,611)	(8,598)	108,554
Finance costs	C	(58,238)	(10,859)	7,794	(61,303)
Finance income		7,660	-	156	7,816
Reversal of financial guarantee provision		619	-	(619)	-
Share of results of equity-accounted investees		16,242	-	-	16,242
Profit from revaluation of investment at FVTPL		16	-	(16)	-
Profit before zakat and income tax		92,062	(19,470)	(1,283)	71,309
Zakat and income tax		(22,991)	-	-	(22,991)
Profit for the period from continuing operations		69,071	(19,470)	(1,283)	48,318
Discontinued Operations					
Loss from discontinued operations, net of Zakat		(1,283)	-	1,283	-
Profit for the period		67,788	(19,470)	-	48,318
Profit attributable to:					
Owners of the Parent Company	A-E	60,699	(19,302)	-	41,397
Non-controlling interests	D, E	7,089	(168)	-	6,921
		67,788	(19,470)	-	48,318

Basic and diluted earnings per share for the prior period have also been restated. The amount of the correction for basis and diluted earning per share was a decrease of ~~ﷲ~~ 0.16 per share for the three months and nine months period ended 30 September 2024.

**SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION
(SPIMACO – ADDWAEIH COMPANY)**

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine-month period ended 30 September 2025

(All amounts in thousands of ﷲ, unless otherwise stated)

24. SUBSEQUENT EVENTS

There are no subsequent events that require disclosure or amendment to the accompanying condensed consolidated interim financial statements.

25. COMPARATIVE FIGURES

Certain minor comparative figures adjustments have been made to conform with the current period's presentation of these condensed consolidated interim financial statements.

26. APPROVAL OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The condensed consolidated interim financial statements have been approved and authorized for issue on 11 Jamadi al-Awwal 1447H (corresponding to 2 November 2025) by the Audit Committee under authorization from the Board of Directors.